Clinical Effects of Interferon Therapy with Special Emphasis on Antitumor Efficacy

Reference

• Balkwill F R, Smyth JF. Interferons in cancer therapy: a reappraisal. Lancet 1987; 2: 317
   PubMedGoogle Scholar
• Baron S, Dianzani F, Stanton G J, Fleischmann WR, Jr. The interferon system. A current review to 1987. University of Texas Press, Austin 1987
   Google Scholar
• Cantell K. Clinical performance of natural human leukocyte interferon. Immunobiol 1986; 172: 231
   PubMed Web of Science ®Google Scholar
• Goldstein D, Laszlo J, Rudnick S. Interferon therapy in cancer. Principles of cancer biotherapy, R K Oldham. Raven Press, New York 1987; 247
   Google Scholar
• Krown SE. Interferon: not just alpha. Cancer Treat Rep 1986; 70: 1353
   PubMedGoogle Scholar
• Lengyel P. On the recent excitement in interferon research. In: Interferons as cell growth inhibitors and antitumor factors. UCLA Symp Molec Cell Biol, new series 1986; 50: 21
   Google Scholar
• Pestka S, Langer J A, Zoon K, Samuel CE. Interferons and their actions. Ann Rev Biochem 1987; 56: 727
   PubMed Web of Science ®Google Scholar
• Strander H. Interferon treatment of human neoplasia. Adv Cancer Res 1986; 46: 1
   PubMed Web of Science ®Google Scholar
• Zoon KC. Human interferons: structure and function. Interferon 9 1987; 1
   Google Scholar
• Bocci V. The physiological interferon response. The Interferon System, S Baron, F Dianzani, G J Stanton, WR Fleischmann, Jr. University of Texas Press, Austin 1987; 177
   Google Scholar
• Billiau A. Interferon β2 as a promotor of growth and differentiation of B cells. Immunol Today 1987; 8: 84
   PubMedGoogle Scholar
• Gresser I. How does interferon inhibit tumor growth? Interferon 1985; 6: 93
   Google Scholar
• Gresser I, Tovey MG. Antitumor effects of interferon. Acta Biochim Biophys 1978; 516: 231
   PubMed Web of Science ®Google Scholar
• Robert K H, Einhorn S, Juliusson G, östlund L, Biberfeld P. Interferon induces proliferation and differentiation in primary chronic lymphocytic leukemia cells. Clin Exp Immunol 1985; 62: 530
   PubMed Web of Science ®Google Scholar
• De Vita VT. Dose-response is alive and well. J Clin Oncol 1986; 4: 1157
   PubMedGoogle Scholar
• Hryniuk WM. Is more better? J Clin Oncol 1986; 4: 621
   PubMedGoogle Scholar
• Grob J J, Collet A M, Munoz M H, Bonerandi JJ. Treatment of large basal-cell carcinomas with intralesional interferon-alpha-2a. Lancet 1988; 1: 878
   PubMedGoogle Scholar
• Feinman R, Siegel D S, Le J, Vilcek J. Interferon-gamma enhances target cell sensitivity to monocyte killing. Cell Immunol 1986; 99: 287
   PubMedGoogle Scholar
• Brosjö Ö. Osteosarcoma and interferon. Studies of human xenografts in the nude mouse. Thesis, Karo-linska Institute, Stockholm 1988
   Google Scholar
• Balkwill FR. Animal model systems to evaluate the antitumor activity of interferons. Clinical aspects of interferons, M Revel. Kluwer, Boston 1988; 307
   Google Scholar
• Maluish A E, Urba W J, Longo D L, et al. The determination of an immunologically active dose of interferon-gamma in patients with melanom. J Clin Oncol 1988; 6: 434
   PubMed Web of Science ®Google Scholar
• Strander H, Boethius J, Erhardt K, et al. Does successful interferon treatment of tumor patients require life-long treatment? J Interferon Res 1987; 7: 619
   Google Scholar
• Bocci V. Pharmacokinetics of interferons and practical implications. Clinical aspects of interferons, M Revel. Kluwer, Boston 1988; 259
   Google Scholar
• Scott G MS. Toxic effects. Clinical aspects of interferons, M Revel. Kluver, Boston 1988; 245
   Google Scholar
• Boiron M. Treatment of virus associated tumors with interferon. Pathol Biol 1986; 34: 1041
   PubMedGoogle Scholar
• World Health Organization: Progress in the development and use of antiviral drugs and interferon. 1987; 754, Technical Report Series
   Google Scholar
• Finter N B, Strander HA. Introduction. Med Clin North Am 1986, Suppl: 1
   PubMedGoogle Scholar
• Friedman-Kien A E, Eron L J, Conant M, et al. Natual interferon alfa for treatment of condylomata acuminata. JAMA 1988; 259: 533
   PubMedGoogle Scholar
• Abrams D I, Volberding PA. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol 1986; 13: 43, Suppl 2
   PubMed Web of Science ®Google Scholar
• Groopman JE. Biology and therapy of epidemic Kaposi's sarcoma. Cancer 1987; 59: 633, Suppl
   PubMedGoogle Scholar
• Odajnyk C, Muggia FM. Treatment of Kaposi's sarcoma: overview and analysis by clinical setting. J Clin Oncol 1985; 3: 1277
   PubMedGoogle Scholar
• Volberding P A, Mitsuyasu R T, Golando J P, Spiegel RJ. Treatment of Kaposi's sarcoma with interferon alfa-2b (In-tron A). Cancer 1987; 59: 620
   PubMedGoogle Scholar
• Braun D P, Harris JE. Abnormal monocyte function in patients with Kaposi's sarcoma. Cancer 1986; 57: 1501
   PubMedGoogle Scholar
• Krown S E, Real F X, Vadhan-Raj S, et al. Kaposi's sarcoma and the required immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors. Cancer 1986; 57: 1662
   PubMedGoogle Scholar
• Flandrin G, Sigaux F, Castaigne, et al. Treatment of hairy cell leukemia with recombinant alpha interferon. I. Quantitative study of bone marrow changes during the first months of treatment. Blood 1986; 67: 817
   PubMed Web of Science ®Google Scholar
• Glaspy J A, Jacobs A D, Golde DW. Evolving therapy of hairy cell leukemia. Cancer 1987; 59: 652, Suppl
   PubMed Web of Science ®Google Scholar
• Quesada J R, Gutterman JU. Alpha interferons in B-cell neoplasms. Br J Haematol 1986; 64: 639
   PubMed Web of Science ®Google Scholar
• Quesada J R, Reuben J, Manning J T, Hersh E M, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl. J Med 1984; 310: 15
   Google Scholar
• Porzdt F, Digel W, Jacobsen H, Mittnacht S, Kirchner H, Heimpel H. Different antitumor mechanisms of interferon-alpha in the treatment of hairy cell leukemia and renal cell cancer. Cancer, 61: 288, 188;
   PubMedGoogle Scholar
• Thompson J A, Fefer A. Interferon in the treatment of hairy cell leukemia. Cancer 1987; 59: 605
   PubMedGoogle Scholar
• Hofmann V, Frey V. Long-term treatment of hairy cell leukemia with interferon alfa-2b. Cancer Treat Rev 1988; 15: 7, Suppl A
   PubMedGoogle Scholar
• Bergsagel DE. Interferon alfa-2b in the management of chronic granulocytic leukemia. Cancer Treat Rev 1988; 15: 15, Suppl A
   PubMedGoogle Scholar
• Talpaz M, Kantarjian H M, Kurzrock R, Gutterman J. Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Semin Hematol 1988; 25: 62
   PubMed Web of Science ®Google Scholar
• Foon K A, Roth M S, Bunn PA, Jr. Interferon therapy of non-Hodgkin's lymphoma. Cancer 1987; 59: 601
   PubMedGoogle Scholar
• Steis R G, Foon K A, Longo DL. Current and future uses of recombinant interferon alpha in the treatment of low grade non-Hodgkin's lymphoma. Cancer 1987; 59: 658, Suppl
   PubMedGoogle Scholar
• Chisesi T, Capnist G, Vespignani M, Dini E. The role of interferon alfa-2b and chlorambucil in the treatment of non-Hodgkin's lymphoma. Cancer Treat Rev 1988; 15: 27, Suppl A
   PubMed Web of Science ®Google Scholar
• Bunn PA, Jr., Ihde D C, Foon KA. Recombinant interferon alfa-2a, an active agent in advanced T-cell lymphomas. Int J Cancer 1987; 9, Suppl 1
   Google Scholar
• Hagberg H, Juhlin L, Scheynius A, Tjernlund U. Low dosage alpha-interferon treatment in patients with advanced cutaneous T-cell lymphoma. Eur J Haematol 1988; 40: 31
   PubMed Web of Science ®Google Scholar
• Brenning G, Nilsson K, Åhre A. Correlation between in vitro and in vivo sensitivity to human leukocyte interferon in patients with multiple myeloma. Scand J Haematol 1985; 35: 543
   PubMedGoogle Scholar
• Kawano M, Hirano T, Matsudo T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83
   PubMed Web of Science ®Google Scholar
• Creagan E T, Ahmann D L, Frytak S, Long H J, Chang M N, Itri LM. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analysis. Cancer 1987; 59: 638, Suppl
   PubMed Web of Science ®Google Scholar
• Creagan E T, Ahmann D L, Long H J, Frytak S, Sherwin S A, Chang MN. Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma. Cancer Treat Rep 1987; 71: 843
   PubMedGoogle Scholar
• von Wussow P, Block B, Hartmann F, Deicher H. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988; 61: 1071
   PubMed Web of Science ®Google Scholar
• Krown SE. Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer 1987; 59: 647, Suppl
   PubMed Web of Science ®Google Scholar
• Berek J S, Hacker N F, Lichtenstein A, et al. Intraperitoneal recombinant α-interferon for ‘salvage’ immunotherapy in stage III epithelial ovarian cancer: a gynecologic oncology group study. Semin Oncol 1986; 13: 61, Suppl 2
   Google Scholar
• Welander CE. Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs. Cancer 1987; 59: 617
   PubMedGoogle Scholar
• Einhorn N, Ling P, Einhorn S, Strander H. A phase II study on escalating interferon doses in advanced ovarian carcinoma. Am J Clin Oncol 1988; 11: 3
   PubMedGoogle Scholar
• Dorval T, Beuzeboc P, Falcoff E. Interferons in breast cancer. Clinical aspects of interferons, M Revel. Kluwer, Boston 1988; 157
   Google Scholar
• Tran R, Hand P H, Greiner J W, Pestka S, Schlom J. Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons. J Interferon Res 1988; 8: 75
   PubMedGoogle Scholar
• Nagai M. Clinical use of interferons in the treatment of malignant brain tumors. Clinical aspects of interferons, M Revel. Kluwer, Boston 1988; 183
   Google Scholar
• Strander H, Bauer H CF, Brosjö O, . Osteosarcoma management and interferon. Clinical aspects of interferons, M Revel, et al. Kluwer, Boston 1988; 165
   Google Scholar
• Itri L A, Campon M, Dennin R A, et al. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection. Cancer 1986; 59: 668, Suppl
   Google Scholar
• Einhorn S, Vanky F, Grandér D, Willems JS. Induction of 2′, 5′-oligoadenylate synthetase in freshly separated malignant cells from solid tumors. Variability in the susceptibility to interferon. Eur J Cancer Clin Oncol 1987; 23: 1607
   PubMedGoogle Scholar
• Dicks J L, Dennis ES. Down's syndrome and hepatitis: an evaluation of carrier status. JAMA 1987; 114: 637
   Google Scholar
• Alkan S S, Towbin H, Hochkeppel HK. Enhanced antiproliferative action of interferon targeted by bispecific monoclonal antibodies. J Interferon Res 1988; 8: 25
   PubMedGoogle Scholar
• Smyth JF. Guidelines for the use of Intron A (interferon alfa-2b) in clinical oncology: lessons from the laboratory. Cancer Treat Rev 1988; 15: 3, Suppl A
   PubMedGoogle Scholar
• Rosenthal C J, Martin M E, Stark R. Cyclophosphamide selectively augments the alpha-2b interferon effects on cytolytic lymphocytes and its clinical efficacy in patients with advanced malignancies. Proc AACR 1988; 29: 416
   Google Scholar
• Schmid S M, Borden EC. Interferons in combination with cytostatic modalitites for cancer treatment. Clinical aspects of interferon, M Revel. Kluwer, Boston 1988; 227
   Google Scholar
• Chang A YC, Keng D. Radiation sensitization by interferons, preclinical and clinical studies. J Interferon Res 1987; 7: 681
   Google Scholar
• Gresser I, Maury C, Belardelli F, Maunoury M T, Machover D. Mouse interferons α/β is more effective than single agent chemotherapy in increasing the survival time of mice after intravenous inoculation of Friend erythroleukemia cells. J Nat Cancer Inst 1988; 80: 126
   PubMedGoogle Scholar